These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 20948320)

  • 1. Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer.
    Merritt WM; Kamat AA; Hwang JY; Bottsford-Miller J; Lu C; Lin YG; Coffey D; Spannuth WA; Nugent E; Han LY; Landen CN; Nick AM; Stone RL; Coffman K; Bruckheimer E; Broaddus RR; Gershenson DM; Coleman RL; Sood AK
    Cancer Biol Ther; 2010 Dec; 10(12):1306-14. PubMed ID: 20948320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.
    Kamat AA; Merritt WM; Coffey D; Lin YG; Patel PR; Broaddus R; Nugent E; Han LY; Landen CN; Spannuth WA; Lu C; Coleman RL; Gershenson DM; Sood AK
    Clin Cancer Res; 2007 Dec; 13(24):7487-95. PubMed ID: 18094433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
    Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
    J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer.
    Kamat AA; Coffey D; Merritt WM; Nugent E; Urbauer D; Lin YG; Edwards C; Broaddus R; Coleman RL; Sood AK
    Cancer; 2009 Jun; 115(12):2684-92. PubMed ID: 19396818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma.
    Lee JW; Stone RL; Lee SJ; Nam EJ; Roh JW; Nick AM; Han HD; Shahzad MM; Kim HS; Mangala LS; Jennings NB; Mao S; Gooya J; Jackson D; Coleman RL; Sood AK
    Clin Cancer Res; 2010 May; 16(9):2562-70. PubMed ID: 20388851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.
    Gökmen-Polar Y; Toroni RA; Hocevar BA; Badve S; Zhao Q; Shen C; Bruckheimer E; Kinch MS; Miller KD
    Breast Cancer Res Treat; 2011 Jun; 127(2):375-84. PubMed ID: 20602165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of EphA2 and VEGF in squamous cell carcinoma of the tongue: correlation with the angiogenesis and clinical outcome.
    Shao Z; Zhang WF; Chen XM; Shang ZJ
    Oral Oncol; 2008 Dec; 44(12):1110-7. PubMed ID: 18485799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer.
    Dasari SK; Joseph R; Umamaheswaran S; Mangala LS; Bayraktar E; Rodriguez-Aguayo C; Wu Y; Nguyen N; Powell RT; Sobieski M; Liu Y; Chowdhury MA; Amero P; Stephan C; Lopez-Berestein G; Westin SN; Sood AK
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma.
    Guidi AJ; Abu-Jawdeh G; Tognazzi K; Dvorak HF; Brown LF
    Cancer; 1996 Aug; 78(3):454-60. PubMed ID: 8697391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer.
    Rahman MT; Nakayama K; Ishikawa M; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Iida K; Miyazaki K
    Oncology; 2013; 84(3):166-73. PubMed ID: 23306391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer.
    Joseph R; Dasari SK; Umamaheswaran S; Mangala LS; Bayraktar E; Rodriguez-Aguayo C; Wu Y; Nguyen N; Powell RT; Sobieski M; Liu Y; Kim MS; Corvigno S; Foster K; Hanjra P; Vu TC; Chowdhury MA; Amero P; Stephan C; Lopez-Berestein G; Westin SN; Sood AK
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNMT3A/3B overexpression might be correlated with poor patient survival, hypermethylation and low expression of ESR1/PGR in endometrioid carcinoma: an analysis of The Cancer Genome Atlas.
    He D; Wang X; Zhang Y; Zhao J; Han R; Dong Y
    Chin Med J (Engl); 2019 Jan; 132(2):161-170. PubMed ID: 30614867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer.
    van Weelden WJ; Lalisang RI; Bulten J; Lindemann K; van Beekhuizen HJ; Trum H; Boll D; Werner HMJ; van Lonkhuijzen LRCW; Yigit R; Forsse D; Witteveen PO; Galaal K; van Ginkel A; Bignotti E; Weinberger V; Sweegers S; Kroep JR; Cabrera S; Snijders MPLM; Inda MA; Eriksson AGZ; ; Krakstad C; Romano A; van de Stolpe A; Pijnenborg JMA
    Am J Obstet Gynecol; 2021 Oct; 225(4):407.e1-407.e16. PubMed ID: 34019887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia contributes to development of recurrent endometrial carcinoma.
    Pijnenborg JM; Wijnakker M; Hagelstein J; Delvoux B; Groothuis PG
    Int J Gynecol Cancer; 2007; 17(4):897-904. PubMed ID: 17359291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The analysis of hormonal status and vascular and cell proliferation in endometrioid endometrial adenocarcinomas.
    Drocaş I; Crăiţoiu Ş; Stepan AE; Iliescu DG; Drocaş IA; Stepan MD
    Rom J Morphol Embryol; 2022; 63(1):113-120. PubMed ID: 36074674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
    Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
    Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma.
    Lee JW; Han HD; Shahzad MM; Kim SW; Mangala LS; Nick AM; Lu C; Langley RR; Schmandt R; Kim HS; Mao S; Gooya J; Fazenbaker C; Jackson D; Tice DA; Landen CN; Coleman RL; Sood AK
    J Natl Cancer Inst; 2009 Sep; 101(17):1193-205. PubMed ID: 19641174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor-D over-expressing tumor cells induce differential effects on uterine vasculature in a mouse model of endometrial cancer.
    Girling JE; Donoghue JF; Lederman FL; Cann LM; Achen MG; Stacker SA; Rogers PA
    Reprod Biol Endocrinol; 2010 Jul; 8():84. PubMed ID: 20615255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist.
    Dobrzanski P; Hunter K; Jones-Bolin S; Chang H; Robinson C; Pritchard S; Zhao H; Ruggeri B
    Cancer Res; 2004 Feb; 64(3):910-9. PubMed ID: 14871820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
    Lax SF; Pizer ES; Ronnett BM; Kurman RJ
    Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.